Last reviewed · How we verify
vancomycin with aztreonam
At a glance
| Generic name | vancomycin with aztreonam |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer (PHASE1)
- Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
- Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) (PHASE3)
- Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis (PHASE2)
- Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (PHASE3)
- Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vancomycin with aztreonam CI brief — competitive landscape report
- vancomycin with aztreonam updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI